Testing individual baroreflex responses to hypoxia-induced peripheral chemoreflex stimulation

Hendrik Kronsbein1,2 · Darius A. Gerlach1 · Karsten Heusser1 · Alex Hoff1 · Fabian Hoffmann1,3 · André Diedrich4 · Heimo Ehmke2,5 · Jens Jordan6 · Jens Tank1

Received: 13 September 2019 / Accepted: 21 December 2019
© The Author(s) 2020

Abstract

Introduction Baroreflexes and peripheral chemoreflexes control efferent autonomic activity making these reflexes treatment targets for arterial hypertension. The literature on their interaction is controversial, with suggestions that their individual and collective influence on blood pressure and heart rate regulation is variable. Therefore, we applied a study design that allows the elucidation of individual baroreflex–chemoreflex interactions.

Methods We studied nine healthy young men who breathed either normal air (normoxia) or an air–nitrogen–carbon dioxide mixture with decreased oxygen content (hypoxia) for 90 min, with randomization to condition, followed by a 30-min recovery period and then exposure to the other condition for 90 min. Multiple intravenous phenylephrine bolus doses were applied per condition to determine phenylephrine pressor sensitivity as an estimate of baroreflex blood pressure buffering and cardiovagal baroreflex sensitivity (BRS).

Results Hypoxia reduced arterial oxygen saturation from 98.1 ± 0.4 to 81.0 ± 0.4% (p < 0.001), raised heart rate from 62.9 ± 2.1 to 76.0 ± 3.6 bpm (p < 0.001), but did not change systolic blood pressure (p = 0.182). Of the nine subjects, six had significantly lower BRS in hypoxia (p < 0.05), two showed a significantly decreased pressor response, and three showed a significantly increased pressor response to phenylephrine in hypoxia, likely through reduced baroreflex buffering (p < 0.05). On average, hypoxia decreased BRS by 6.4 ± 0.9 ms/mmHg (19.9 ± 2.0 vs. 14.12 ± 1.6 ms/mmHg; p < 0.001) but did not change the phenylephrine pressor response (p = 0.878).

Conclusion We applied an approach to assess individual baroreflex–chemoreflex interactions in human subjects. A subgroup exhibited significant impairments in baroreflex blood pressure buffering and BRS with peripheral chemoreflex activation. The methodology may have utility in elucidating individual pathophysiology and in targeting treatments modulating baroreflex or chemoreflex function.

Keywords Cardiovascular · Blood pressure · Pharmacological baroreflex · Chemoreflex · Phenylephrine
Introduction

Arterial baroreflexes and peripheral chemoreflexes have been implicated in the pathogenesis of arterial hypertension and identified as treatment targets [1]. Both originate from receptors, namely, the carotid sinus baroreceptors and carotid body chemoreceptors, respectively, located in close proximity to the carotid bifurcation [2, 3]. Baroreflexes buffer changes in blood pressure through counter-regulatory adjustments in efferent sympathetic and parasympathetic activity and affect long-term blood pressure control [4], and carotid body chemoreceptor stimulation raises sympathetic activity [5]. In arterial hypertension, the sympathetic baroreflex gain is depressed and the baroreflex is reset to higher blood pressure [6]; in contrast, carotid chemoreceptors are sensitized [7–9] and generate tonic sympathetic activation [10–13] in hypertensive patients. Baroreceptor and carotid body afferents converge onto neurons in the dorsomedial medulla [14], resulting in an inhibitory interaction [15, 16]. Thus, impaired baroreflex regulation in arterial hypertension may be mediated in part through inappropriate carotid body chemoreceptor activation [1, 9]. Electrical carotid sinus stimulators and stents augmenting baroreceptor transmission as well as peripheral chemoreceptor modulation have been developed for hypertension management; however, all baroreflex modulating procedures developed to date exhibit an unacceptably high proportion of non-responders [17–20]. Blood pressure reductions following such interventions are likely determined by interindividual differences in baroreflex–chemoreflex interactions, which are not uncovered through routine clinical testing. While human baroreflex–chemoreflex interactions have been previously investigated [16, 21, 22], we hypothesized that a combination of physiological profiling and multiple repeated measurements could be utilized to elucidate individual baroreflex–chemoreflex interactions. In our study, hypoxia served as the peripheral chemoreceptor stimulus. In a similar fashion, patients have been repeatedly exposed to test and control interventions, such as statin and placebo treatment, to elucidate individual responses in so-called N-of-one trials [23, 24].

Methods

Subjects

Nine healthy young men with a mean age of 28.8 ± 3.0 years and a mean body mass index of 23.8 ± 0.8 kg/m² were enrolled in the study (Table 1). Medical history and results from the physical examination, resting electrocardiogram, spirometry, and routine blood testing were all in the normal range. The ethics committee of the North Rhine medical association approved the study, and the study was registered in the German Clinical Trials register (DRKS00013101). Written informed consent was obtained from each participant before study entry.

Protocol

All measurements were obtained with the subjects in the supine position after they had voided their bladder. We assessed non-invasive beat-to-beat blood pressure (Finapres® NOVA; Finapres Medical Systems, Enschede, The Netherlands), upper arm blood pressure, arterial oxygen saturation, end-tidal carbon dioxide (ETCO₂) concentration, breathing frequency, tidal volume, minute ventilation (Innoccor; Innovision, Odense, Denmark), and an electrocardiogram recording (Vital Guard 450C; Ivy Biomedical Systems, Inc., Branford, CT, USA). An antecubital venous catheter was set in place for drug administration. Baseline data were recorded for 10 min prior to starting the randomized protocol (Table 1).

Table 1 Baseline characteristics of subjects (n = 9)

| Subject | SBP (mmHg) | DBP (mmHg) | HR (bpm) | BMI (kg/m²) | Age (years) |
|---------|------------|------------|----------|-------------|-------------|
| 01      | 126        | 78         | 61       | 27.4        | 37          |
| 02      | 136        | 78         | 61       | 24.5        | 30          |
| 03      | 122        | 74         | 65       | 22.6        | 24          |
| 04      | 132        | 82         | 66       | 24.5        | 38          |
| 05      | 136        | 70         | 67       | 24.2        | 20          |
| 06      | 125        | 80         | 79       | 21.2        | 22          |
| 07      | 139        | 82         | 48       | 24.3        | 34          |
| 08      | 127        | 62         | 80       | 20.8        | 24          |
| 09      | 127        | 72         | 55       | 22.6        | 33          |

Values in table are the baseline characteristics of each subject taken before the beginning of the first session

SBP Systolic blood pressure, DBP diastolic blood pressure, HR heart rate, BMI body mass index
We first determined the individual dose of the alpha-
1-adrenoreceptor agonist phenylephrine that was needed
to raise to blood pressure by 20–30 mmHg, using incre-
mental doses of between 25 and 100 µg. All phenylephrine
doses were immediately followed by a 10-ml saline flush.
Both procedures were conducted in a standardized fash-
ion using an automated bolus injector (Accutron MR;
Medtron AG, Saarbrücken, Germany). Bolus flow rates
were 5 ml/s for phenylephrine and 2.5 ml/s for the saline
bolus, resulting in administration durations of 4.1–4.4
s. Following determination of the appropriate dose, we
obtained repeated baroreflex measurements using the pre-
determined phenylephrine dose, with the subjects exposed
either to normoxic or hypoxic condition for 90 min,
with randomization to one or the other condition and
single blinding (subjects). Following the first exposure,
subjects were allowed to recover for 30 min during which
time they could stand up and empty their bladder, with the
aim to minimize any carry-over effects from being supine
or hypoxic, before being exposed for 90 min to the other
condition. In the first 10 min of each exposure, inspiratory
oxygen was slowly lowered to attain hypoxia or kept con-
stant for normoxia testing. Thereafter, 20 phenylephrine
bolus doses were applied, one every 4 min. The study pro-
tocol is illustrated in Fig. 1.

**Hypoxic peripheral chemoreflex stimulation**

We utilized a hypoxic gas mixture containing nitrogen,
oxigen, and carbon dioxide. Compressed air and nitrogen
were mixed in a blender (Bird™ Blender low flow;
Vyaire Medical Inc., Mettawa, IL, USA). Carbon dioxide
was added separately in order to maintain normocapnia.
Gas flows were controlled using flowmeters and buffered
in a Douglas bag from which the subject could inhale with-
out resistance or pressure via a face mask. For normocap-
nic hypoxia, the target was 80% arterial oxygen satura-
tion, achieved by manual adjustment. To keep subjects
blind to the condition, the same toolset was used to apply
compressed air during both the hypoxia and normoxia
procedures.

**Baroreflex measurements**

Two parameters that characterize baroreflex function were
assessed, namely, cardiovagal baroreflex sensitivity (BRS)
and baroreflex buffering capacity. For both measurements
we utilized the increase in finger blood pressure after the
administration of each phenylephrine bolus. This pharma-
cological approach ensures greater independence from ventila-
tory influences on baroreflex function than methods based
on spontaneous variations in hemodynamic variables. The
investigator was blinded to the condition, i.e., normoxia or
hypoxia.

1. Cardiovagal BRS was assessed as the slope of the
regression line between each systolic blood pressure
(SBP) value and the following RR interval during the
phenylephrine-induced pressure rise without an offset
[25, 26]. The slope was accepted if Pearson’s correlation
coefficient \( r > 0.5 \) [27].

2. Larger increases in blood pressure after the administra-
tion of a defined phenylephrine bolus denote reduced the
baroreflex buffering capacity. We determined this phe-
nylephrine sensitivity as rise in SBP (ΔSBP) from the
baseline before each bolus to the SBP maximum after
bolus application [28]. Baseline SBP was calculated by
averaging ten readings taken before each bolus. Maxi-
mum SBP was obtained by averaging the three highest
consecutive SBP values within 60 s after each bolus.

**Statistics**

Individual BRS and phenylephrine responses were ana-
yzed using unpaired \( t \) tests. For group comparisons, we
used medians of up to 20 boli per condition in order to
minimize the effect of possible outliers and analyzed these
via the paired \( t \) test. Significance was assumed at \( p < 0.05.\)
If not otherwise indicated, all values were expressed as
the mean ± SE. Power for BRS and change in SBP were

---

**Fig. 1** Schematic illustration
of the study protocol. *Phe* Phen-
ylephrine
calculated post hoc by means of the statistical analysis tool G*Power 3.1. We estimated the number of bolus repetitions needed to estimate individual effects between normoxia and hypoxia with receiver operating characteristic curve analysis performed with SPSS V.21 software (IBM Corp., Armonk, NY, USA). All other statistical analyses were done using Graphpad Prism 7.04 (GraphPad Software Inc., San Diego, CA, USA).

**Results**

All subjects tolerated baroreflex testing in both normoxia and hypoxia, and no adverse events were observed. Arterial oxygen saturation was 98.1 ± 0.4% during normoxia and 81.0 ± 0.4% during hypoxia (p < 0.001), and ETCO₂ remained at baseline values (38.31 ± 0.9 [normoxia] vs. 37.78 ± 1.1 mmHg [hypoxia]; p = 0.245). Respiratory rate (16 ± 1 vs. 16 ± 1/min; p = 0.588) did not change. During hypoxia, tidal volume increased from 0.77 ± 0.04 to 0.95 ± 0.07 l (p = 0.002), and minute ventilation increased from 11.86 ± 0.51 to 13.95 ± 0.49 l/min (p = 0.036); the mean respiratory chemoreflex response (ΔVe/SpO₂) was 11.79 ± 4.80 (l/min)/%

Blood pressure was 133 ± 3/76 ± 2 mmHg during normoxia and 135 ± 3/76 ± 2 mmHg during hypoxia. During the experiment systolic blood pressure ranged from 122 to 154 mmHg during normoxia and from 121 to 148 mmHg during hypoxia. Heart rate increased from 63 ± 2 bpm during normoxia to 76 ± 4 bpm during hypoxia (p < 0.001). Figure 2 illustrates original blood pressure and RR-interval responses to repeated phenylephrine doses during normoxia and during hypoxia in one subject.

Individual baroreflex responses are given in Tables 2, 3, and Fig. 3. Not all phenylephrine applications yielded responses suitable for baroreflex analysis. The number of bolus doses analyzed for each subject and condition ranged between 8 and 20 (Tables 2, 3). In hypoxia, BRS was significantly lower in six subjects; Figure 3a illustrates individual changes in BRS, including the 95% confidence intervals, with reductions in BRS during hypoxia in these six subjects. Overall BRS decreased from 19.9 ± 2.0 ms/mmHg in normoxia to 14.1 ± 1.6 ms/mmHg in hypoxia (p < 0.001; power 0.995; Fig. 3a).

Five subjects showed a significant change in phenylephrine responsiveness with hypoxic peripheral chemoreflex stimulation (Table 3), with phenylephrine responsiveness significantly decreasing in two subjects and significantly increasing in three subjects. In the other four subjects, phenylephrine sensitivity did not change significantly. Overall, phenylephrine responsiveness did not change (p = 0.878), as shown in Fig. 3b, which plots individual changes in phenylephrine sensitivity, including the 95% confidence intervals, and indicates the high interindividual variability.

The optimal number of repetitions for individual BRS changes was ten bolii with a sensitivity of 0.96. This is derived from our heathy subjects with an effect size of 6 ± 3 ms/mmHg (difference in BRS between normoxia and hypoxia). Overall, we did not observe a linear correlation between changes in BRS or phenylephrine responsiveness and respiratory parameters (respiratory rate, tidal volume, or minute ventilation). Individual respiratory parameters varied, as shown in Table 4.

Hemodynamic reactions were stable over time during normoxia and hypoxia (Fig. 2). The sequence of the conditions normoxia and hypoxia did not affect BRS or phenylephrine responsiveness measurements.

We could not find a correlation between changes in cardiac BRS and baroreflex buffering capacity (Fig. 4).

**Discussion**

In the study reported here, we applied a novel approach to elucidate individual baroreflex–chemoreflex interactions using repeated administrations of a standardized phenylephrine bolus during normoxia and hypoxia. While individual and group cardiovagal BRS responses to hypoxic peripheral chemoreceptor stimulation showed similar qualitative responses, individual responses exhibited substantial quantitative variability. Strikingly, individual phenylephrine responsiveness revealed qualitatively different responses, possibly resulting from changes in vascular sensitivity, in baroreflex blood pressure buffering, or in both mechanisms combined [28]. Our findings provide insight into human autonomic cardiovascular control mechanisms and could be useful in individualized assessment of baroreflex–chemoreflex interactions in patients with arterial hypertension, particularly in those considered for interventions targeting these reflexes.

The highly standardized assessment of baroreflex function using phenylephrine doses applied through an automated injector is a particular strength of our study. In previous studies, vasoactive drugs for baroreflex testing as well as subsequent saline flushes were manually applied [21, 29]. The lack of standardization likely introduces variability in drug delivery, immediate vascular responses, and subsequent baroreflex counter regulation. Our approach reduced this variability source. Another strength of our study is the large number of repeated phenylephrine tests which, unlike in previous studies, allowed for individual assessment of the baroreflex–chemoreflex interaction. We found that ten bolii with a significant cardiovagal baroreflex response could be the appropriate number of bolii for an optimal estimation.
Fig. 2 Original recording of RR-interval (RRI) and systolic blood pressure (SBP) responses to phenylephrine bolus given during normoxia (a) and hypoxia (b), as well as corresponding peripheral capillary oxygen saturation (SpO2) curves (c). a, b Black arrows show timepoints at which phenylephrine bolus were injected; the black upper lines correspond to RRI with the RRI axis on the left, and the lower gray lines correspond to SBP with the axis on the right side.
Table 2 Individual baroreflex responses of the nine subjects in normoxia and hypoxia

| Subject | Order of condition applied (condition applied first) | Normoxia | Hypoxia | Statistical analysis |
|---------|-----------------------------------------------------|----------|---------|---------------------|
|         |                                                     | BRS (ms/mmHg) | Boli (n) | BRS (ms/mmHg) | boli (n) | p value | t      |
| 01      | Hypoxia                                             | 19.6±2.1  | 17      | 18.3±1.4  | 19      | 0.603   | 0.525  |
| 02      | Normoxia                                           | 14.9±1.4  | 16      | 9.5±1.4   | 17      | 0.011   | 2.689  |
| 03      | Hypoxia                                             | 18.9±1.9  | 18      | 11.4±1.2  | 17      | 0.002   | 3.307  |
| 04      | Normoxia                                           | 14.4±1.2  | 19      | 11.1±2.1  | 17      | 0.159   | 1.439  |
| 05      | Normoxia                                           | 29.0±2.0  | 14      | 19.6±1.9  | 16      | 0.002   | 3.381  |
| 06      | Hypoxia                                             | 14.7±1.2  | 16      | 10.1±0.9  | 17      | 0.017   | 2.533  |
| 07      | Normoxia                                           | 28.6±3.3  | 16      | 16.8±2.6  | 8       | 0.028   | 2.35   |
| 08      | Hypoxia                                             | 14.4±0.8  | 20      | 8.3±0.8   | 20      | <0.001  | 5.399  |
| 09      | Hypoxia                                             | 24.9±1.6  | 19      | 21.1±1.8  | 17      | 0.122   | 1.585  |

**BRS** Baroreflex sensitivity

BRS values are presented as the individual mean values ± standard error of the mean (SEM), together with the corresponding number of boli. p values and t correspond to measurements in normoxia vs. those in hypoxia. Significance was assumed at p < 0.05.

Table 3 Change in systolic blood pressure in normoxia and hypoxia in the nine subjects

| Subject | Order of condition applied (condition applied first) | Normoxia | Hypoxia | Statistical analysis |
|---------|-----------------------------------------------------|----------|---------|---------------------|
|         |                                                     | ΔSBP (mmHg) | Boli (n) | ΔSBP (mmHg) | Boli (n) | p value | t      |
| 01      | Hypoxia                                             | 17.6±1.2  | 20      | 21.8±1.4  | 20      | 0.026   | 2.31   |
| 02      | Normoxia                                           | 25.7±2.7  | 20      | 23.2±2.9  | 17      | 0.531   | 0.633  |
| 03      | Hypoxia                                             | 27.8±1.1  | 20      | 31.0±2.4  | 20      | 0.232   | 1.214  |
| 04      | Normoxia                                           | 19.4±1.7  | 19      | 29.7±2.3  | 18      | 0.001   | 3.576  |
| 05      | Normoxia                                           | 18.1±1.6  | 19      | 24.1±2.2  | 20      | 0.033   | 2.21   |
| 06      | Hypoxia                                             | 30.0±1.7  | 20      | 26.0±2.0  | 20      | 0.1396  | 1.509  |
| 07      | Normoxia                                           | 17.1±1.8  | 20      | 13.0±1.4  | 20      | 0.069   | 1.872  |
| 08      | Hypoxia                                             | 30.3±1.3  | 20      | 22.2±1.1  | 20      | <0.001  | 4.714  |
| 09      | Hypoxia                                             | 19.1±1.2  | 20      | 12.5±1.9  | 20      | 0.006   | 2.943  |

ΔSBP values are presented as individual mean values ± SEM, together with the corresponding number of boli. p values and t correspond to measurements in normoxia vs. those in hypoxia. Significance was assumed at p < 0.05.

Fig. 3 Forest plots of individual changes (hypoxia–normoxia) in cardiovagal baroreflex sensitivity (**BRS**) (a) and individual changes in phenylephrine sensitivity (b). Data points indicate mean difference in BRS or SBP increase between hypoxia and normoxia, and error bars indicate the range of these differences (95% confidence interval). p values are shown next to each data point, and asterisks, where present, indicate significance of difference (*p < 0.05; **p < 0.01; ***p < 0.001).
We observed complex changes in baroreflex regulation with hypoxic peripheral chemoreflex stimulation. Average blood pressure was unchanged while the heart rate increased substantially. The baroreflex heart rate/pressure relationship was shifted towards higher heart rates and cardiovagal BRS was reduced. Increases in heart rate and maintained or increased blood pressure with peripheral chemoreflex stimulation have been previously described; in these studies sympathetic and parasympathetic baroreflex gains [21, 22, 30, 31] and baroreflex responsiveness [32] did not change. However, in two studies, chemoreflex-induced resetting of baroreflex-mediated sympathetic vasomotor control to higher blood pressure levels was observed using spontaneous baroreflex threshold [21] and modified Oxford techniques [29]. We speculate that the discrepancy in cardiovagal BRS responses may result in part from the methodology to assess baroreflex function or the high variability which we reduced through repeated testing. Interindividual and between-study variability in the BRS response to hypoxic chemoreceptor stimulation may partly result from variability in chemosensitivity [33].

Baroreflex regulation of sympathetic traffic to the vasculature is particularly relevant for blood pressure control. However, direct sympathetic nerve recordings are available in only a few medical centers and the tests often fail for technical reasons. As an alternative, the primary function of the baroreflex, which is to buffer blood pressure changes, can be assessed by applying vasoactive drugs before and during complete interruption of the baroreflex arc through ganglionic blockade [28]; the sensitivity to vasoactive drugs changes less in individuals with less efficient baroreflex blood pressure buffering than in those with more efficient baroreflex blood pressure buffering. Influences of gender, age, autonomic failure, and arterial hypertension on blood pressure buffering have been previously assessed [34–36]. Ganglionic blockers are no longer available for investigations on humans, and the methodology is cumbersome. Approximately 80% of the variability in systemic phenylephrine pressor sensitivity can be attributed to variability in baroreflex buffering rather than to vascular responsiveness [28]. That analysis included healthy persons and patients with various disorders known to affect vascular alpha-adrenoreceptor responsiveness. Therefore, phenylephrine responses without ganglionic blockade may provide an estimate of baroreflex buffering capacity. Thus, the results of our study may suggest that there is a dissociation between cardiovagal BRS and baroreflex blood pressure buffering during hypoxic chemoreflex stimulation.

The major limitation of our study is that findings in healthy subjects cannot be simply extrapolated to patients

### Table 4  Respiration parameters recorded for each of the nine subjects throughout each session in normoxia or hypoxia

| Subject | Respiratory rate (breaths/min) | Tidal volume (l) | Minute ventilation (l/min) | ΔSpO2 (%) | ΔVe/ΔSpO2 (l/min/%) |
|---------|--------------------------------|-----------------|---------------------------|-----------|---------------------|
|         | Normoxia                        | Hypoxia         | Normoxia                  | Hypoxia   |                     |
| 0.1     | 9.53 ± 0.10                     | 13.04 ± 0.08    | 1.05 ± 0.02               | 1.33 ± 0.01 | 9.33 ± 0.12         | 16.86 ± 0.11 | 17.30 | 43.53 |
| 0.2     | 17.11 ± 0.05                    | 17.95 ± 0.13    | 0.80 ± 0.00               | 0.88 ± 0.01 | 13.64 ± 0.06        | 15.67 ± 0.15 | 18.51 | 11.11 |
| 0.3     | 14.13 ± 0.11                    | 12.55 ± 0.16    | 0.87 ± 0.01               | 1.13 ± 0.02 | 11.62 ± 0.09        | 12.48 ± 0.14 | 16.53 | 5.25  |
| 0.4     | 16.30 ± 0.09                    | 16.02 ± 0.09    | 0.73 ± 0.01               | 0.83 ± 0.01 | 11.64 ± 0.05        | 12.77 ± 0.10 | 16.40 | 6.91  |
| 0.5     | 19.12 ± 0.08                    | 20.26 ± 0.08    | 0.69 ± 0.01               | 0.73 ± 0.01 | 12.53 ± 0.07        | 14.13 ± 0.08 | 16.86 | 9.48  |
| 0.6     | 19.13 ± 0.08                    | 17.36 ± 0.12    | 0.73 ± 0.01               | 0.76 ± 0.01 | 13.66 ± 0.05        | 12.50 ± 0.09 | 15.29 | −7.57 |
| 0.7     | 18.89 ± 0.09                    | 14.09 ± 0.13    | 0.74 ± 0.01               | 1.04 ± 0.02 | 13.17 ± 0.08        | 13.52 ± 0.20 | 16.89 | 2.05  |
| 0.8     | 18.29 ± 0.07                    | 18.3 ± 0.09     | 0.62 ± 0.00               | 0.77 ± 0.00 | 11.13 ± 0.03        | 13.64 ± 0.05 | 19.03 | 13.20 |
| 0.9     | 14.15 ± 0.08                    | 13.19 ± 0.08    | 0.72 ± 0.00               | 1.07 ± 0.01 | 10.02 ± 0.06        | 13.94 ± 0.08 | 17.74 | 22.11 |

Ve Minute ventilation, SpO2 peripheral capillary oxygen saturation, ΔVe/ΔSpO2 mean respiratory chemoreflex response

Where appropriate, values are given as the mean ± SEM

![Fig. 4](image)

Correlation analysis between changes in cardiovagal baroreflex sensitivity and phenylephrine sensitivity. Phenylephrine sensitivity is considered as a marker of baroreflex-mediated buffering of blood pressure

Ve Minute ventilation, SpO2 peripheral capillary oxygen saturation, ΔVe/ΔSpO2 mean respiratory chemoreflex response

Where appropriate, values are given as the mean ± SEM

### Table 4  Respiration parameters recorded for each of the nine subjects throughout each session in normoxia or hypoxia

| Subject | Respiratory rate (breaths/min) | Tidal volume (l) | Minute ventilation (l/min) | ΔSpO2 (%) | ΔVe/ΔSpO2 (l/min/%) |
|---------|--------------------------------|-----------------|---------------------------|-----------|---------------------|
|         | Normoxia                        | Hypoxia         | Normoxia                  | Hypoxia   |                     |
| 0.1     | 9.53 ± 0.10                     | 13.04 ± 0.08    | 1.05 ± 0.02               | 1.33 ± 0.01 | 9.33 ± 0.12         | 16.86 ± 0.11 | 17.30 | 43.53 |
| 0.2     | 17.11 ± 0.05                    | 17.95 ± 0.13    | 0.80 ± 0.00               | 0.88 ± 0.01 | 13.64 ± 0.06        | 15.67 ± 0.15 | 18.51 | 11.11 |
| 0.3     | 14.13 ± 0.11                    | 12.55 ± 0.16    | 0.87 ± 0.01               | 1.13 ± 0.02 | 11.62 ± 0.09        | 12.48 ± 0.14 | 16.53 | 5.25  |
| 0.4     | 16.30 ± 0.09                    | 16.02 ± 0.09    | 0.73 ± 0.01               | 0.83 ± 0.01 | 11.64 ± 0.05        | 12.77 ± 0.10 | 16.40 | 6.91  |
| 0.5     | 19.12 ± 0.08                    | 20.26 ± 0.08    | 0.69 ± 0.01               | 0.73 ± 0.01 | 12.53 ± 0.07        | 14.13 ± 0.08 | 16.86 | 9.48  |
| 0.6     | 19.13 ± 0.08                    | 17.36 ± 0.12    | 0.73 ± 0.01               | 0.76 ± 0.01 | 13.66 ± 0.05        | 12.50 ± 0.09 | 15.29 | −7.57 |
| 0.7     | 18.89 ± 0.09                    | 14.09 ± 0.13    | 0.74 ± 0.01               | 1.04 ± 0.02 | 13.17 ± 0.08        | 13.52 ± 0.20 | 16.89 | 2.05  |
| 0.8     | 18.29 ± 0.07                    | 18.3 ± 0.09     | 0.62 ± 0.00               | 0.77 ± 0.00 | 11.13 ± 0.03        | 13.64 ± 0.05 | 19.03 | 13.20 |
| 0.9     | 14.15 ± 0.08                    | 13.19 ± 0.08    | 0.72 ± 0.00               | 1.07 ± 0.01 | 10.02 ± 0.06        | 13.94 ± 0.08 | 17.74 | 22.11 |
with arterial hypertension, particularly those considered for device-based treatments targeting the baroreflex or peripheral chemoreceptors. The fact that we did not assess sympathetic nerve activity is another potential limitation. Moreover, we determined an estimate of baroreflex blood pressure buffering rather than making a comparison phenylephrine responses before and after ganglionic blockade for the reasons mentioned above. While much of the interindividual variability in phenylephrine responsiveness can be explained by baroreflex blood pressure buffering, hypoxia-induced changes in vascular alpha-adrenoreceptor responsiveness may have confounded the analysis. However, data from human [37] and animal studies [38] regarding direct vascular actions of hypoxia are controversial, and it is evident that changes in vascular tone during hypoxia cannot be solely explained by baroreflex-mediated changes in adrenergic drive. Our observed BRS and phenylephrine responsiveness shift with hypoxia may be the result of hypoxia-induced vasodilation [39, 40]. Furthermore, hypoxia-induced heart rate changes are not abolished following bilateral carotid body removal [41]. However, in patients with resistant arterial hypertension, reductions in sympathetic traffic and blood pressure with electrical carotid sinus stimulation were found to be virtually identical with and without hypoxia [42]. This observation excludes major changes in the coupling between sympathetic activity and vasoconstriction with hypoxia. ETCO$_2$, which affects cardiovascular control, was kept constant during our study. While we applied hypoxia in a steady-state fashion, transient hypoxia has been proposed to provide a more selective peripheral chemoreceptor stimulus [43]. Finally, hypoxia may have a prolonged effect on sympathetic activity [44]—although the sequence of normoxia and hypoxia sessions in our study did not affect our results. Moreover, we did not observe a substantial sustained effect of hypoxia on sympathetic activity or the response to electrical carotid sinus stimulation in patients with treatment-resistant arterial hypertension [42].

Despite these limitations, our study suggests that interindividual variability of baroreflex and chemoreflex regulation is so high that treatments modulating these mechanisms are exceedingly unlikely to be equally effective in all patients. In recent years there has been a thrust towards precision medicine [45]. Usually, the term implicates molecular assessment of a disease trait, such as somatic mutations in a specific cancer, that results in a targeted intervention. Outside oncology, the merits of the approach in common conditions, including arterial hypertension, have been limited; indeed, molecular signatures guiding hypertension treatment do not exist. However, individual physiological profiling could be utilized to identify underlying mechanisms driving hypertension and to direct treatments to patients more likely to respond. Our study suggests that repeated phenylephrine testing during normoxia and during hypoxia deserves to be tested in this setting.

Acknowledgements Open Access funding provided by Projekt DEAL. We thank the volunteers for participating in this study and Christine Becker for the support during the recruitment process. We are grateful to Dr. Bernd Johannes for the statistics consultation.

Funding FH was supported by DLR grant 50WB1816.

Data availability The raw data supporting the conclusions of this manuscript are available at the following link: https://figshare.com/s/5fbc3c89925cece758d4. This includes the raw analog sampled data from beat-to-beat blood pressure, arterial oxygen saturation, ETCO$_2$ concentration, breathing frequency, tidal volume, minute ventilation, and an electrocardiogram.

Compliance with ethical standards

Conflict of interest The authors declare that they do not have any conflict of interest.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

References

1. Paton JF, Sobotka PA, Fudim M, Engelman ZJ, Hart EC, McBryde FD, Abdala AP, Marina N, Gourine AV, Lobo M, Patel N, Burchell A, Ratcliffe L, Nightingale A (2013) The carotid body as a therapeutic target for the treatment of sympathetically mediated diseases. Hypertension 61(1):5–13
2. Lindsey BG, Nuding SC, Segers LS, Morris KF (2018) Carotid bodies and the integrated cardiorespiratory response to hypoxia. Physiology (Bethesda). 33(4):281–297
3. Benarroch EE (2008) The arterial baroreflex: functional organization and involvement in neurologic disease. Neurology 71(21):1733–1738
4. Lohmeier TE, Iliescu R (2015) The baroreflex as a long-term controller of arterial pressure. Physiology (Bethesda) 30(2):148–158
5. Saito M, Mano T, Iwase S, Koga K, Abe H, Yamazaki Y (1988) Responses in muscle sympathetic activity to acute hypoxia in humans. J Appl Physiol 65(4):1548–1552
6. Eckberg DL (1979) Carotid baroreflex function in young men with borderline blood pressure elevation. Circulation 59(4):632–636
7. Somers VK, Mark AL, Abboud FM (1988) Potentiation of sympathetic nerve responses to hypoxia in borderline hypertensive subjects. Hypertension 11(6 Pt 2):608–612
8. Trzebiński A, Taflił M, Ziółkowski M, Przybyszki J (1982) Increased sensitivity of the arterial chemoreceptor drive in young men with mild hypertension. Cardiovasc Res 16(3):163–172

Springer
(2016) Comparing and characterizing transient and steady-state tests of the peripheral chemoreflex in humans. Exp Physiol 101(3):432–447

44. Xie A, Skatrud JB, Puleo DS, Morgan BJ (2001) Exposure to hypoxia produces long-lasting sympathetic activation in humans. J Appl Physiol 91(4):1555–1562

45. Collins FS, Varmus H (2015) A new initiative on precision medicine. N Engl J Med. 372(9):793–795